Method for diagnosing rheumatoid arthritis

• US 5,395,753 A
• Filed: 02/19/1993
• Issued: 03/07/1995
• Est. Priority Date: 02/19/1993
• Status: Expired due to Fees

• Current Assignee: Watson Pharmaceuticals, Inc. (Abbvie Incorporated), Theratech, Inc. (Dynatronics Corporation)
• Original Assignee: Theratech, Inc. (Dynatronics Corporation)
• Inventors: Prakash, Ramesh K.
• Primary Examiner(s): Wax, Robert A.
• Assistant Examiner(s): GRIMES, ERIC BURTON
• Application Number:
  US08/019,780
• Time in Patent Office: 746 Days
• Field of Search: 435/7.92, 435/69.3, 435/5, 435/6, 435/7.1, 435/7.9, 435/7.92, 435/21, 436/506, 436/513, 436/543
• US Class Current: 435/7.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/4713 Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
• CPC Class Codes: G01N 2800/102 Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Abstract

A method is described for diagnosing rheumatoid arthritis by providing a recombinant IgM-specific rheumatoid arthritis-associated antigen and detecting antibodies against the antigen in patient sera. Preliminary steps of making a cDNA library from polyadenylated RNA purified from human cells, selecting recombinants that express the antigen, recloning cDNA containing the antigen gene in a high level expression vector, expressing the antigen in transformed cells, and purifying the antigen are also described.

Claims

1. A method for diagnosing rheumatoid arthritis comprising the steps of:

(a) providing a recombinant RAMA antigen that is specifically detectable by rheumatoid arthritis-associated IgM antibodies;

(b) incubating said RAMA antigen with patient serum to form a complex of said RAMA antigen and said IgM antibodies; and

(c) detecting said complex as a measure of said IgM antibodies against said RAMA antigen in patient sera.

2. The method as in claim 1 wherein providing said recombinant RAMA antigen comprises the preliminary steps of:

(a) making a cDNA library from polyadenylated RNA purified from human cells, wherein said library is prepared by randomly cloning cDNA derived from said polyadenylated RNA in a cloning vector such that recombinant vectors are produced;

(b) selecting recombinant vectors that express said recombinant RAMA antigen;

(c) expressing said recombinant RAMA antigen in a host containing the recombinant vector; and

(d) purifying the recombinant RAMA antigen.

3. The method as in claim 2 wherein step (a) further comprises making a cDNA library from polyadenylated RNA purified from an Epstein-Barr virus-transformed human B lymphocyte cell line.

4. The method as in claim 3 wherein the Epstein-Bar virus-transformed cell line is the Raji cell line.

5. The method as in claim 2 wherein step (a) further comprises purifying the polyadenylated RNA by oligo(dT) cellulose chromatography.

6. The method as in claim 2 wherein step (a) further comprises cloning the cDNA library using phage λ

gt11 as the cloning vector.

7. The method as in claim 2 wherein step (b) further comprises selecting said recombinant vectors that express said recombinant RAMA antigen by permitting antibodies in sera from clinically-confirmed rheumatoid arthritis patients to bind to said RAMA antigen and then detecting said bound antibodies.

8. The method as in claim 7 wherein said bound antibodies are detected colorimetrically by binding an IgM anti-human antibody-alkaline phosphatase conjugate and providing one or more alkaline phosphatase color development substrates.

9. The method as in claim 8 wherein the color development substrates are nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate.

10. The method as in claim 2 wherein step (c) further comprises growing host cells containing the recombinant vector to an optimum cell density and then inducing expression of the recombinant RAMA antigen.

11. The method as in claim 10 wherein induction of expression is by addition of IPTG to the nutrient medium.

12. The method as in claim 2 wherein step (c) further comprises expressing said recombinant RAMA antigen in E. coli cells.

13. The method as in claim 2 wherein step (c) further comprises expressing said recombinant RAMA antigen in insect cells.

14. The method as in claim 2 further comprising a step intermediate between steps (b) and (c) wherein cloned cDNA from a selected recombinant vector is recloned in a plasmid expression vector.

15. The method as in claim 14 wherein the plasmid expression vector contains nucleotides encoding a metal binding domain having high affinity for an affinity chromatography matrix containing a metal moiety.

16. The method as in claim 15 wherein the plasmid expression vector is a baculovirus vector capable of protein expression in insect cells.

17. The method as in claim 2 wherein step (d) further comprises purifying said recombinant RAMA antigen by affinity chromatography.

18. The method as in claim 17 wherein said recombinant RAMA antigen contains residues comprising a metal binding domain that has high affinity for an affinity chromatography matrix containing a metal moiety.

19. The method as in claim 18 wherein the affinity chromatography matrix contains a metal moiety and is capable of reversibly binding said metal binding domain.

20. The method as in claim 1 wherein step (b) further comprises detecting by reacting said complex with an enzyme-labeled anti-IgM antibody.

21. The method as in claim 20 wherein said RAMA antigen is attached to a solid surface and then patient sera are tested for the presence of antibodies that bind said antigen.

22. The method as in claim 21 wherein the enzyme is alkaline phosphatase.

23. The method as in claim 22 wherein anti-IgM antibody bound to said complex is detected by reacting said alkaline phosphatase with p-nitrophenylphosphate.